Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)-Reference-Cited by-同舟云学术

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

Published:2022-04 Issue:2 Volume:12 Page:
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Aldalaan Abdullah M.¹^ORCID,Saleemi Sarfraz A.¹,Weheba Ihab¹,Abdelsayed Abeer¹,Aleid Maha M.²,Alzubi Fatima¹,Zaytoun Hamdeia¹,Alharbi Nadeen¹

Affiliation:

1. Department of Medicine, Pulmonary Hypertension Program King Faisal Specialist Hospital & Research Center Riyadh Saudi Arabia

2. Department of Biostatistics, Epidemiology & Scientific Computing King Faisal Specialist Hospital & Research Center Riyadh Saudi Arabia

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pul2.12083

Reference35 articles.

1. Diagnosis and treatment of pulmonary hypertension;Nauser TD;Am Fam Physician,2001

2. Haemodynamic definitions and updated clinical classification of pulmonary hypertension

3. Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension: Pathophysiology and Treatment

5. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endor;Galiè N;Eur Respir J,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review;Journal of the American Heart Association;2024-07-02

2. Impression life with pulmonary hypertension: clinically relevant characteristics and quality of life among patients in Gansu, China;Therapeutic Advances in Respiratory Disease;2024-01

3. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry;Pulmonary Pharmacology & Therapeutics;2023-10